GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Mirion
Who owns Mirion Technologies?
Mirion Technologies went public in late 2021 via a SPAC merger with GS Acquisition Holdings Corp II, backed by an affiliate of Goldman Sachs, valuing the enterprise at about $2.6 billion. The company now trades on NYSE under ticker MIR and serves nuclear, medical, and defense sectors.
Originally formed in 2005 from three industry firms, Mirion evolved from private equity rollups to a widely held public company with institutional shareholders and a market cap near $2.85 billion as of late 2025. See Mirion Porter's Five Forces Analysis for product context.
Who Founded Mirion?
Founders and early ownership of Mirion Technologies originated from a private equity consolidation led by American Capital Strategies in 2005, with Thomas Logan installed as founding CEO and American Capital retaining a controlling stake; management and legacy shareholders held the remainder under strict vesting aligned to a buy-and-build strategy.
Private equity genesis
American Capital provided primary equity to merge MGP Instruments, IST and Global Dosimetry Solutions in 2005.
Founding CEO
Thomas Logan was appointed founding CEO to lead integration and execution of the consolidation plan.
Ownership split
American Capital held in excess of 80% ownership at inception; remaining equity went to management and legacy shareholders.
Vesting and incentives
Management equity was subject to strict vesting schedules to align with American Capital’s exit timeline.
Buy-and-build execution
More than a dozen acquisitions were completed early on, financed by debt plus additional American Capital equity injections.
Dilution, value creation
Management’s percentage ownership diluted over time while absolute equity value increased through consolidation and revenue growth.
The initial phase showed no reported ownership disputes and emphasized operational consolidation, with American Capital’s > 80% controlling interest shaping Mirion company ownership and the Mirion Technologies ownership structure explained by private equity control; see Growth Strategy of Mirion for additional context: Growth Strategy of Mirion
Key facts and metrics
Early capital structure and governance drove acquisition-led scale and positioned Mirion for later transactions and investor exits.
- American Capital initial equity > 80%
- Thomas Logan appointed founding CEO in 2005
- Over a dozen bolt-on acquisitions completed during the early buy-and-build phase
- Management equity under multi-year vesting schedules to support exit alignment
Complete Mirion Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
How Has Mirion’s Ownership Changed Over Time?
The ownership of Mirion shifted from private equity control to public institutional dominance through key events: Charterhouse's 2015 buyout and the October 20, 2021 de‑SPAC listing via GS Acquisition Holdings Corp II, which injected approximately 825 million dollars of cash and carried significant equity rollover by Charterhouse and management.
| Year | Event | Impact |
|---|---|---|
| 2015 | Charterhouse Capital Partners acquisition (~750 million dollars) | Shift to private equity ownership; expansion of medical segment (Sun Nuclear) |
| 2021 | De‑SPAC IPO via GS Acquisition Holdings Corp II (Oct 20, 2021) | Public listing; 825 million dollars cash proceeds; rollover equity by Charterhouse/management |
| 2025 Q4 | Institutional ownership concentration | Institutions hold > 92% of outstanding shares; Vanguard ~10.8%, BlackRock ~8.1% |
The transition from a private equity‑led strategy to a public, institutionally owned firm reprioritized Mirion company ownership toward quarterly earnings predictability and clearer capital allocation, while insiders such as founding CEO Thomas Logan retain material stakes (~1.4%), and Goldman Sachs—originating as SPAC sponsor—holds about 4.9%.
Ownership snapshot and implications
Major stakeholders now drive governance and investor relations, emphasizing transparency and steady growth.
- Institutional investors own over 92% of shares
- Top holders: Vanguard (~10.8%), BlackRock (~8.1%), Goldman Sachs (~4.9%)
- Founder/insider stake: Thomas Logan ~1.4%
- Private equity influence reduced after equity rollover at IPO
For more on strategic positioning after these ownership changes see Marketing Strategy of Mirion
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
Who Sits on Mirion’s Board?
The Mirion Technologies board of directors is a nine-member body chaired by Lawrence Kingsley, includes CEO Thomas Logan, and is majority independent under NYSE standards, aligning governance with institutional and industry expertise while limiting unilateral control by any single investor.
| Director | Role | Representative Interest |
|---|---|---|
| Lawrence Kingsley | Chair | Independent industrial executive |
| Thomas Logan | Chief Executive Officer | Management |
| Independent Director A | Director | Healthcare sector oversight |
| Independent Director B | Director | Defense sector expertise |
| Institutional Representative | Director | Major shareholder block |
| Independent Director C | Director | Financial governance |
| Independent Director D | Director | Regulatory/compliance |
| Independent Director E | Director | Operational oversight |
| Independent Director F | Director | Investor relations |
Mirion employs a one-share-one-vote common stock structure so voting power tracks economic ownership; large institutional holders such as Vanguard and BlackRock therefore hold the most influence, and there are no golden shares or dual-class mechanisms to insulate management.
Board composition and voting summary
The board's nine-member makeup is majority independent and includes the CEO, ensuring management accountability while reflecting major institutional interests.
- Single class common stock: one-share-one-vote
- Major institutional shareholders (Vanguard, BlackRock) hold highest voting power
- No dual-class shares, golden shares, or founder super-voting rights
- No major proxy fights through 2025; Medical segment margin focus continues
For governance context and company ethos see Mission, Vision & Core Values of Mirion.
Mirion Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What Recent Changes Have Shaped Mirion’s Ownership Landscape?
Institutional consolidation accelerated through 2024–2025 as early SPAC backers exited and long-only fundamental funds increased exposure; management completed a $150,000,000 buyback in mid-2025 and revenue guidance for 2025 approached $940,000,000, reinforcing investor confidence in Mirion company ownership trends.
| Development | Timing | Impact |
|---|---|---|
| SPAC investor exits; long-only funds enter | 2024–2025 | Higher quality institutional base; increased stability |
| $150,000,000 share buyback | Mid‑2025 | Reduced share count; greater concentration of major holders |
| Small European nuclear monitoring acquisitions (cash‑funded) | 2024–2025 | M&A funded internally; no dilution; matured capital structure |
| Legacy private equity trimming (Charterhouse era) | 2024–2025 | Rising free float; public market liquidity maintained |
| De‑leveraging progress | Late‑2025 | Net debt-to-adjusted EBITDA below 2.8x; favored by institutions |
Ownership dynamics show an upward shift in free float and institutional accumulation, with no public privatization plans as management leverages public-market liquidity to pursue acquisition-led growth; see related background in Brief History of Mirion.
Institutional Base Strengthening
Long-only funds have replaced early SPAC backers, improving stability and aligning with Mirion Technologies investors focused on fundamentals.
Capital-Structure Maturation
Cash-funded bolt-on deals in Europe and a completed $150,000,000 buyback reduced dilution and concentrated major shareholdings.
De‑leveraging Focus
Management targets a net debt-to-adjusted EBITDA ratio under 2.8x, appealing to current institutional holders and supporting valuation metrics.
Liquidity and Future M&A
Higher free float and public listing provide liquidity for continued Mirion Technologies acquisition activity without resorting to dilutive equity.
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Brief History of Mirion Company?
- What is Competitive Landscape of Mirion Company?
- What is Growth Strategy and Future Prospects of Mirion Company?
- How Does Mirion Company Work?
- What is Sales and Marketing Strategy of Mirion Company?
- What are Mission Vision & Core Values of Mirion Company?
- What is Customer Demographics and Target Market of Mirion Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.